Ariad investors retreat on FDA probe of Iclusig
This article was originally published in Scrip
After taking a beating earlier in the week, shares of Ariad Pharmaceuticals were pounded again on 11 October, tumbling as low as 22%, after US regulators said they had opened a probe into the increase in reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the company's oral leukemia drug Iclusig (ponatinib), a kinase inhibitor.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.